Tagged with

regulation The general manager of Algeria’s pharmaceuticals regulator narrates the founding and evolution of the institution, how it has been flexing its muscles with the withdrawal of no less than 17 products from the local market, and how the body has been selected to play a leading role in the WHO’s Expert Advisory Panel on…

manufacturing The CEO of one of Algeria’s most successful pharmaceutical firms describes how El Kendi became the first foreign firm to be established in Algeria without having a mother company abroad. He also lifts the lid on the secrets behind the firms extraordinary track record for speed in securing product registration and approval on…

government The leader of the commission for health in the Algerian parliament’s upper chamber speaks out about new legislation under review, identifies other shortcomings in the country’s healthcare system and even gives personal insights from her own career as a medical practitioner alongside her political activities. Can you please start by outlining the role…

clinical trials The global CEO of Arianne, who herself happens to be American-Algerian, outlines why, in an era of clinical research globalisation, the country has all the right fundamentals in place to establish itself as a leader in conducting clinical trials and how the Algerian genetic code is well suited for testing Western orientated pharmaceutical…

clinical trials LSK Global PS CEO Young-Jack Lee discusses the influence of global CROs on the quality of Korean research, and outlines his own strategy for competing in the marketplace and growth outside of Korea.   When we met you in 2008, you were positive about the growth of Korean CROs and…

Sanofi Sanofi’s Korean affiliate is the fifth largest recipient of clinical trial investments after the United States, France, Germany and the United Kingdom. Kay Bae, general manager, discusses the benefits of clinical testing in Korea and why ‘open innovation’ is important for progress and development.   You became general manager of…

medical devices Song In-Keum, chairman of the Korean Medical Devices Industry Association (KMDIA), discusses current opportunities offered by Korea’s growing medtech industry.   What have been your priorities since you became the chairman of the organization? The medical device industry is considered as one of the fastest growing industries in Korea, at present…

partnering The Korean Institute of Toxicology (KIT) is a government-funded research institute that evaluates the safety of medicine, bio-related products and chemicals. PharmaBoardroom talks to Lee Sang-Joon, President of KIT about his current operations and his vision for the future.     Can you discuss the role that KIT plays today…

partnering Korea possesses enormous potential to become an exporter of futuristic health systems in the near future, and has already started the process. Kim Han-Joong, chairman of the strategy committee at CHA Health Systems, outlines Korea’s strengths in healthcare and its forward-looking vision for the future.   You became chairman of…

innovation The Korea Drug Research Association (KDRA) was founded in 1986 to represent local pharmaceutical companies in their mission for global drug development. Kang-Choo Lee, president of KDRA, discusses the current scenario for local companies and outlines his ambitions for making Korea a global hub for innovation.   Since we met…

clinical trials The president of Astellas Korea offers his perspectives on Korea as a base for primary and clinical research, and the company’s recent partnerships in the country.   You became president of Astellas Korea in 2011, following a long career at this affiliate. What were the biggest objectives you had when…

clinical trials The head researcher at P&K Skin Research Center discusses the potential of South Korea as a clinical trial hub, and the company’s current expansion plans.   What differentiates P&K Skin from its competitors, and what are the key characteristics of the Korean market that attract foreign patients and companies? We…